Safety of long‐term intranasal budesonide delivered via the mucosal atomization device for chronic rhinosinusitis

Abstract

These findings suggest that there is a risk of adrenal suppression and raised IOP associated with the long-term use of topical nasal budesonide via MAD. Otolaryngologists should consider periodic surveillance for these adverse events in this patient cohort.